Sonoma Pharmaceuticals, Inc. (SNOA)
Stock Price Chart
Key Info
| Market Cap | 15.46M |
| Revenue (ttm) | 18.94M |
| Net Income (ttm) | -2.95M |
| Shares Out | 1.97M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $7.85 |
| Previous Close | $8.34 |
| Change ($) | -0.49 |
| Change (%) | -5.88% |
| Day's Open | 8.37 |
| Day's Range | 7.80 - 8.37 |
| Day's Volume | 72,595 |
| 52-Week Range | 3.33 - 19.60 |
More Stats
| Market Cap | 15.46M |
| Enterprise Value | 13.24M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 1.97M |
| Float | 1.94M |
| EPS (basic) | -1.99 |
| EPS (diluted) | -2.00 |
| FCF / Share | -3.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 15,181 |
| Short Ratio | 0.43 |
| Short % of Float | 27.27% |
| Beta | 1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.82 |
| PB Ratio | 1.89 |
| Revenue | 18.94M |
| Operating Income | -3.10M |
| Net Income | -2.95M |
| Free Cash Flow | -4.80M |
| Net Cash | 2.21M |
| Net Cash / Share | 1.12 |
| Gross Margin | 44.01% |
| Operating Margin | -16.37% |
| Profit Margin | -15.60% |
| FCF Margin | -25.33% |
| ROA | -28.75% |
| ROE | -30.70% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.94 | 18.97 | 16.66 | 12.83 | 9.37 | 13.85 | 13.67 | 15.45 | 12.74 | 9.75 |
| Revenue Growth | -0.18% | 13.88% | 29.89% | 36.89% | -32.37% | 1.36% | -11.55% | 21.25% | 30.65% | - |
| Gross Profit | 8.33 | 8.88 | 7.31 | 5.67 | 2.65 | 7.29 | 8.40 | 10.74 | 8.71 | 6.14 |
| Operating Income | -3.10 | -11.26 | -14.50 | -12.97 | -14.71 | -6.66 | -6.05 | -3.37 | -6.47 | -7.51 |
| Net Income | -2.95 | -11.80 | -14.33 | 9.27 | -10.16 | -8.20 | 3.74 | -5.43 | -7.33 | -7.95 |
| Shares Outstanding | 1.48 | 0.92 | 0.50 | 0.47 | 0.37 | 0.21 | 0.15 | 0.11 | 0.09 | 0.08 |
| Earnings Per Share | -1.99 | -12.77 | -28.49 | 19.80 | -27.81 | -38.25 | 24.30 | -58.50 | -84.15 | -94.50 |
| Operating Cash Flow | -4.59 | -11.72 | -12.44 | -8.17 | -8.75 | -6.69 | -4.89 | 1.15 | -4.03 | -4.43 |
| Capital Expenditures | -0.21 | -0.10 | -0.19 | -0.39 | -0.35 | -0.14 | -0.50 | -0.26 | -0.34 | -0.17 |
| Free Cash Flow | -4.80 | -11.82 | -12.63 | -8.56 | -9.09 | -6.83 | -5.39 | 0.89 | -4.37 | -4.60 |
| Cash & Equivalents | 3.69 | 3.69 | 10.07 | 17.46 | 7.47 | 6.14 | 5.48 | 7.90 | 3.35 | 4.37 |
| Total Debt | 1.48 | 0.48 | 0.55 | 0.41 | 0.11 | 0.09 | 0.15 | 1.94 | 3.24 | 2.55 |
| Net Cash / Debt | 2.21 | 3.21 | 9.51 | 17.05 | 7.36 | 6.05 | 5.33 | 5.97 | 0.11 | 1.83 |
| Assets | 14.56 | 14.45 | 19.21 | 25.46 | 13.80 | 15.05 | 20.79 | 12.57 | 7.84 | 8.66 |
| Liabilities | 5.86 | 3.96 | 3.88 | 4.03 | 3.66 | 2.99 | 8.73 | 8.48 | 8.71 | 6.96 |
| Book Value | 8.71 | 10.49 | 15.33 | 21.43 | 10.14 | 12.05 | 12.06 | 4.08 | -0.87 | 1.70 |
Company Profile
Company Details
| Full Name | Sonoma Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 19 |
| CEO | Amy M. Trombly |
Stock Information
| Ticker Symbol | SNOA |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NASDAQ: SNOA |
| IPO Date | January 25, 2007 |
Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.